132 related articles for article (PubMed ID: 29231047)
1. Cost-effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma.
Rognoni C; Ciani O; Sommariva S; Tarricone R
J Comp Eff Res; 2018 Mar; 7(3):209-221. PubMed ID: 29231047
[TBL] [Abstract][Full Text] [Related]
2. Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Rognoni C; Ciani O; Sommariva S; Tarricone R
Value Health; 2017 Mar; 20(3):336-344. PubMed ID: 28292478
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis.
Chen S; Peng Z; Wei M; Liu W; Dai Z; Wang H; Mei J; Cheong M; Zhang H; Kuang M
BMC Cancer; 2018 Apr; 18(1):392. PubMed ID: 29621988
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma.
Rostambeigi N; Dekarske AS; Austin EE; Golzarian J; Cressman EN
J Vasc Interv Radiol; 2014 Jul; 25(7):1075-84. PubMed ID: 24861664
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hepatocellular carcinoma: a cost analysis of yttrium-90 transarterial radioembolization versus sorafenib.
Lucà MG; Nani R; Schranz M; De Giorgio M; Iegri C; Agazzi R; Sala F; Virotta G; Sarti D; Conte G; Pinelli D; Nicora C; Colledan M; Sironi S; Fagiuoli S
Future Oncol; 2018 Apr; 14(8):727-735. PubMed ID: 29578364
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting.
Thein HH; Qiao Y; Zaheen A; Jembere N; Sapisochin G; Chan KKW; Yoshida EM; Earle CC
PLoS One; 2017; 12(10):e0185198. PubMed ID: 29016627
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma.
Zhao RC; Zhou J; Wei YG; Liu F; Chen KF; Li Q; Li B
Hepatobiliary Pancreat Dis Int; 2017 Oct; 16(5):493-498. PubMed ID: 28992881
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
[TBL] [Abstract][Full Text] [Related]
9. Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis.
Rognoni C; Ciani O; Sommariva S; Bargellini I; Bhoori S; Cioni R; Facciorusso A; Golfieri R; Gramenzi A; Mazzaferro V; Mosconi C; Ponziani F; Sacco R; Trevisani F; Tarricone R
BMC Cancer; 2018 Jul; 18(1):715. PubMed ID: 29976149
[TBL] [Abstract][Full Text] [Related]
10. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.
Kim DY; Han KH
Hepatol Int; 2016 Nov; 10(6):883-892. PubMed ID: 27126821
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns and direct medical costs among patients with advanced hepatocellular carcinoma.
Aly A; Malangone-Monaco E; Noxon V; Henriques C; Benavente F; Kim A
Curr Med Res Opin; 2020 Nov; 36(11):1813-1823. PubMed ID: 32969741
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis.
Shlomai A; Leshno M; Goldstein DA
PLoS One; 2018; 13(11):e0207132. PubMed ID: 30408106
[TBL] [Abstract][Full Text] [Related]
14. Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.
Cai H; Zhang L; Li N; Zheng B; Liu M
J Comp Eff Res; 2020 Jun; 9(8):553-562. PubMed ID: 32419473
[No Abstract] [Full Text] [Related]
15. Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic review.
Alonso JC; Casans I; González FM; Fuster D; Rodríguez A; Sánchez N; Oyagüez I; Burgos R; Williams AO; Espinoza N
BMC Gastroenterol; 2022 Jul; 22(1):326. PubMed ID: 35780112
[TBL] [Abstract][Full Text] [Related]
16. Transarterial Chemoembolization and (90)Y Radioembolization for Hepatocellular Carcinoma: Review of Current Applications Beyond Intermediate-Stage Disease.
Fidelman N; Kerlan RK
AJR Am J Roentgenol; 2015 Oct; 205(4):742-52. PubMed ID: 26397322
[TBL] [Abstract][Full Text] [Related]
17. Drug effect analysis of sorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma.
Xu X; Meng Q
Pak J Pharm Sci; 2018 Jul; 31(4(Special)):1751-1755. PubMed ID: 30203774
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt.
Hamdy Elsisi G; Nada Y; Rashad N; Carapinha J
J Med Econ; 2019 Feb; 22(2):163-168. PubMed ID: 30479174
[TBL] [Abstract][Full Text] [Related]
19. Transarterial chemoembolization and sorafenib in hepatocellular carcinoma.
Cabibbo G; Tremosini S; Galati G; Mazza G; Gadaleta-Caldarola G; Lombardi G; Antonucci M; Sacco R
Expert Rev Anticancer Ther; 2014 Jul; 14(7):831-45. PubMed ID: 24850249
[TBL] [Abstract][Full Text] [Related]
20. Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma.
Vadot L; Boulin M; Guiu B; Aho LS; Vourc'h M; Musat A; Hillon P; Lepage C; Guignard MH; Fagnoni P
J Clin Pharm Ther; 2015 Feb; 40(1):83-90. PubMed ID: 25413186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
